B of A Securities upgraded Haemonetics (NYSE:HAE) from Neutral to Buy on May 22, 2026. The broker’s analysts project a 35.40% upside, with an average one-year price target of $83.87 per share, compared to the latest reported closing price of $61.94.
The projected annual revenue for Haemonetics is $1.275 billion, reflecting a decrease of 4.42%. Additionally, institutional ownership has decreased by 46.10% over the last quarter, with total shares owned decreasing by 17.97% to 52 million shares. The put/call ratio stands at 0.21, indicating a bullish market sentiment.
Major shareholders include Neuberger Berman Group with 3.56 million shares (7.66% ownership) and Aqr Capital Management holding 3.36 million shares (7.22% ownership), both adjusting their positions in HAE recently.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
